Joint Survival Analysis of Time to Drug Change and a Terminal Event with Application to Drug Failure Analysis using Transplant Registry Data

Authors

  • Elizabeth Renouf Department of Statistical and Actuarial Sciences, University of Western Ontario, London, Ontario, N6A 5B7, Canada
  • C.B. Dean Department of Statistical and Actuarial Sciences, University of Western Ontario, London, Ontario, N6A 5B7, Canada
  • David R. Bellhouse Department of Statistical and Actuarial Sciences, University of Western Ontario, London, Ontario, N6A 5B7, Canada
  • Vivian C. McAlister Department of Surgery, University of Western Ontario, London, Ontario, N6A 5B7, Canada

DOI:

https://doi.org/10.6000/1929-6029.2016.05.03.6

Keywords:

Joint models, longitudinal, survival, transplant, joint outcome

Abstract

Statistical approaches for drug effectiveness studies after liver transplant have used a survival model with changes in treatment as a time-dependent covariate. However, the approach requires that changes in the time-dependent covariate be unrelated to survival outcome. Usually this is not the case, as one drug may be discontinued and an alternative chosen due to the declining health status of the patient. Other approaches examine only subjects who remain on the same drug over a time window, which discards valuable data and may lead to biased effects since this excludes data related to early deaths and to individuals who perform poorly on the drug and had to switch treatments. Because of these issues there are conflicting results seen in the evaluation of immunosuppressive drug effectiveness after liver transplant. We propose a joint survival outcome model with a time-to-drug-change event and a terminal event in graft failure that is useful in drug effectiveness studies where subjects are discontinued from an immunosuppressant (in favour of alternative treatment) due to health reasons. We also include a longitudinal biomarker component. The model takes account of the dependencies across out- comes through shared random effects. Using a Markov chain Monte Carlo approach, we fit the joint model to data from liver transplant recipients from the Scientific Registry for Transplant Recipients.

References

Hadley S, Samore MH, Lewis WD, Jenkins RL, Karchmer AW, Hammer SM. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995; 59(6): 851-858. http://dx.doi.org/10.1097/00007890-199503000-00009 DOI: https://doi.org/10.1097/00007890-199503000-00009

Watt KD, Dierkhising R, Heimbach JK, Charlton MR. Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients database. Liver Transplantation 2012; 18(9): 1029-1036. http://dx.doi.org/10.1002/lt.23479 DOI: https://doi.org/10.1002/lt.23479

Fisher LD, Lin DY. Time-dependent covariates in the cox proportional-hazards regression model. Annual Review of Public Health 1999; 20(1): 145-157. http://dx.doi.org/10.1146/annurev.publhealth.20.1.145 DOI: https://doi.org/10.1146/annurev.publhealth.20.1.145

Liu L, Wolfe RA, Huang X. Shared frailty models for recurrent events and a terminal event. Biometrics 2004; 60(3): 747-756. http://dx.doi.org/10.1111/j.0006-341X.2004.00225.x DOI: https://doi.org/10.1111/j.0006-341X.2004.00225.x

Chi Y, Ibrahim JG. Joint models for multivariate longitudinal and multivariate survival data. Biometrics 2006; 62(2): 432-445. DOI: https://doi.org/10.1111/j.1541-0420.2005.00448.x

Rondeau V, Mathoulin-Pelissier S, Jacqmin-Gadda H, Brute V, Soubeyran P. Joint frailty models for recurring events and death using maximum penalized likelihood estimation: application on cancer events. Biostatistics 2007; 8(4): 708-721. http://dx.doi.org/10.1093/biostatistics/kxl043 DOI: https://doi.org/10.1093/biostatistics/kxl043

Rondeau V, Michiels S, Liquet B, Pignon J-P. Investigating trial and treatment heterogeneity in an individual patient data meta-analysis of survival data by means of the penalized maximum likelihood approach. Statistics in Medicine 2008; 27(11): 1894-1910. http://dx.doi.org/10.1002/sim.3161 DOI: https://doi.org/10.1002/sim.3161

Liu L, Huang X. Joint analysis of correlated repeated measures and recurrent events processes in the presence of death, with application to a study on acquired immune deficiency syndrome. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2009; 58(1): 65-81. http://dx.doi.org/10.1111/j.1467-9876.2008.00641.x DOI: https://doi.org/10.1111/j.1467-9876.2008.00641.x

Musoro JZ, Geskus RB, Zwinderman AH. A joint model for repeated events of different types and multiple longitudinal outcomes with application to a follow-up study of patients after kidney transplant. Biometrical Journal 2015; 57(2): 185-200. http://dx.doi.org/10.1002/bimj.201300167 DOI: https://doi.org/10.1002/bimj.201300167

Elashoff RM, Li, G, Li N. An approach to joint analysis of longitudinal measurements and competing risks failure time data. Statistics in Medicine 2007; 26(14): 2813. http://dx.doi.org/10.1002/sim.2749 DOI: https://doi.org/10.1002/sim.2749

Elashoff RM, Li, G, Li N. A joint model for longitudinal measurements and survival data in the presence of multiple failure types. Biometrics 2007; 64(3): 762-771. http://dx.doi.org/10.1111/j.1541-0420.2007.00952.x DOI: https://doi.org/10.1111/j.1541-0420.2007.00952.x

Williamson PR, Kolamunnage-Dona R, Philipson P, Marson AG. Joint modelling of longitudinal and competing risks data. Statistics in Medicine 2008; 27(30): 6426-6438. http://dx.doi.org/10.1002/sim.3451 DOI: https://doi.org/10.1002/sim.3451

Xu J, Kalbfleisch JD, Tai B. Statistical analysis of illness-death processes and semicompeting risks data. Biometrics 2010; 66(3): 716-725. http://dx.doi.org/10.1111/j.1541-0420.2009.01340.x DOI: https://doi.org/10.1111/j.1541-0420.2009.01340.x

Han B, Yu M, Dignam JJ, Rathouz PJ. Bayesian approach for flexible modeling of semicompeting risks data. Statistics in Medicine 2014; 33(29): 5111-5125. http://dx.doi.org/10.1002/sim.6313 DOI: https://doi.org/10.1002/sim.6313

Rouanet A, Joly P, Dirties JF, Proust-Lima C, Jacqmin-Gadda H. Joint latent class model for longitudinal data and interval-censored semi-competing events: Application to dementia. Biometrics 2015; 59: 1-23.

Dickinson DM, Ellison MD, Webb RL. Data sources and structure. American Journal of Transplantation 2003; 3(s4): 13-28. http://dx.doi.org/10.1034/j.1600-6143.3.s4.3.x DOI: https://doi.org/10.1034/j.1600-6143.3.s4.3.x

R Development Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, 2010.

Plummer M et al. Jags: A program for analysis of Bayesian graphical models using Gibbs sampling. Proceedings of the 3rd international workshop on distributed statistical computing. 2003; 124: 125-132.

Brooks SP, Gelman A. General methods for monitoring convergence of iterative simulations. Journal of Computational and Graphical Statistics 1998; 7(4): 434-455. DOI: https://doi.org/10.1080/10618600.1998.10474787

Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51(4): 1237-1243. http://dx.doi.org/10.1002/hep.23437 DOI: https://doi.org/10.1002/hep.23437

McKenna GJ, Trotter JF, Klintmalm E, Onaca N, Ruiz R, Jennings LW, Neri N, O’Leary JG, Davis GL, Levy MF, et al. Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression. American Journal of Transplantation 2011; 11(11): 2379- 2387. http://dx.doi.org/10.1111/j.1600-6143.2011.03767.x DOI: https://doi.org/10.1111/j.1600-6143.2011.03767.x

Howell J, Angus P, Gow P. Hepatitis C recurrence: the Achilles heel of liver transplantation. Transplant Infectious Disease 2014; 16(1): 1-16. http://dx.doi.org/10.1111/tid.12173 DOI: https://doi.org/10.1111/tid.12173

Odell PM, Anderson KM, and Ralph B D’Agostino. Maximum likelihood estimation for interval-censored data using a Weibull-based accelerated failure time model. Biometrics 1992; 951-959. http://dx.doi.org/10.2307/2532360 DOI: https://doi.org/10.2307/2532360

Rucker G, Messerer D. Remission duration: An example of interval-censored observations. Statistics in Medicine 1988; 7(11): 1139-1145. http://dx.doi.org/10.1002/sim.4780071106 DOI: https://doi.org/10.1002/sim.4780071106

Downloads

Published

2016-08-16

How to Cite

Renouf, E., Dean, C., R. Bellhouse, D., & C. McAlister, V. (2016). Joint Survival Analysis of Time to Drug Change and a Terminal Event with Application to Drug Failure Analysis using Transplant Registry Data. International Journal of Statistics in Medical Research, 5(3), 198–213. https://doi.org/10.6000/1929-6029.2016.05.03.6